192 related articles for article (PubMed ID: 12588434)
1. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
[TBL] [Abstract][Full Text] [Related]
2. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
[TBL] [Abstract][Full Text] [Related]
3. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
4. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
5. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
8. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
9. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
12. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
[TBL] [Abstract][Full Text] [Related]
13. Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis.
Hadzisejdić I; Mustać E; Jonjić N; Petković M; Grahovac B
Mod Pathol; 2010 Mar; 23(3):392-403. PubMed ID: 20062009
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.
Mylona E; Tzelepis K; Theohari I; Giannopoulou I; Papadimitriou C; Nakopoulou L
Histopathology; 2013 Feb; 62(3):472-80. PubMed ID: 23163571
[TBL] [Abstract][Full Text] [Related]
15. Cytologic evaluation of cyclin D1 expression in primary breast carcinoma.
Park K; Han S; Kim HY; Ko I
Cancer; 2001 Jun; 93(3):211-5. PubMed ID: 11391609
[TBL] [Abstract][Full Text] [Related]
16. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.
Pelosio P; Barbareschi M; Bonoldi E; Marchetti A; Verderio P; Caffo O; Bevilacqua P; Boracchi P; Buttitta F; Barbazza R; Dalla Palma P; Gasparini G
Ann Oncol; 1996 Sep; 7(7):695-703. PubMed ID: 8905027
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients.
Reed W; Flørems VA; Holm R; Hannisdal E; Nesland JM
Virchows Arch; 1999 Aug; 435(2):116-24. PubMed ID: 10599310
[TBL] [Abstract][Full Text] [Related]
19. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients.
Umekita Y; Ohi Y; Sagara Y; Yoshida H
Int J Cancer; 2002 Mar; 98(3):415-8. PubMed ID: 11920593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]